Clinical Trial

An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Study acronym: MAGNOLIA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of the study is to demonstrate non-inferiority of ANB-002 compared with preventive use of coagulation factor IX (FIX) in adult subjects with hemophilia B with FIX activity ≤2% and without FIX inhibitor. The study will have an open-label single-arm design.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-19; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-02-19
Trial Details
NCT Number NCT06700096
Lead Sponsor Biocad
Conditions Hemophilia B
Enrollment 24 participants
Start Date 2024-11-07
Primary Completion 2027-04 (estimated)
Study Completion 2032-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-18